Perbandingan Konsentrasi IgE Air Mata Penderita Alergi Okuli dengan Pemberian Pemirolast Potassium 0,1% dan Sodium Cromoglycate 4%

Authors

  • Hariwati Moehariadi Laboratorium Ilmu Kesehatan Mata Rumah Sakit Umum Dr. Saiful Anwar Malang
  • Yasmine Yasmine Laboratorium Ilmu Kesehatan Mata Rumah Sakit Umum Dr. Saiful Anwar Malang

DOI:

https://doi.org/10.21776/ub.jkb.2012.027.02.11

Abstract

Penyakit alergi okuli adalah penyakit alergi pada konjungtiva atau kulit kelopak mata, berhubungan dengan reaksi inflamasi karena menempelnya immunoglobulin  E (IgE) di sel mast. Penatalaksanaan penyakit alergi okuli meliputi meminimalkan kontak dengan alergen dan pemberian obat-obatan (antihistamin, stabilisator sel mast  (sodium cromoglycate, pemirolast potassium, lodoxamide, nedocromil sodium), kombinasi antihistamin dan stabilisator sel mast (kortikosteroid, siklosporin). Tujuan penelitian ini adalah untuk mengetahui penurunan konsentrasi IgE dan perbedaan penurunan konsentrasi IgE penderita alergi okuli sesudah diterapi dengan pemirolast potassium 0,1% atau sodium cromoglycate 4%.Penelitian ini merupakan pre and post clinical trial design pada 32 penderita alergi okuli. Sebanyak 16 penderita mendapatkan tetes mata pemirolast potassium  0,1% dan 16 lainnya mendapatkan tetes mata sodium cromoglycate 4%. Air mata penderita diambil saat datang dan satu minggu setelah terapi untuk pemeriksaan konsentrasi IgE dan diperiksa menggunakan ELISA reader. Penurunan konsentrasi IgE sebelum dan setelah terapi pada masing-masing obat diuji menggunakan uji T-test dependent, sedangkan perbandingan penurunan konsentrasi IgE antara kedua obat diuji menggunakan uji T-test independent. Pada kelompok pemirolast potassium 0,1%, konsentrasi IgE awal 730,73 ± SD 40,17 IU/ml dan menurun menjadi 678,61 ± SD 56,20 IU/ml. Kelompok sodium cromoglycate 4%, konsentrasi IgE awal 731,16 ± SD 32,13 IU/ml dan menurun menjadi 686,73 ± SD 43,08 IU/ml(p=0,000). Perbedaan penurunan konsentrasi IgE pada kelompok pemirolast potassium 0,1% sebesar 52,12 ± SD 41,00 IU/ml, kelompok sodium cromoglycate 4% sebesar 44,43 ± SD 32,63 IU/ml. Perbedaan penurunan konsentrasi IgE antara kedua obat tidak bermakna (p=0,561). Dapat disimpulkan  tidak didapatkan perbedaan bermakna efek pemirolast potassium 0,1% dan sodium cromoglycate 4% dalam menurunkan konsentrasi IgE air mata penderita alergi okuli.

Downloads

Download data is not yet available.

References

Bielory L and Friedlaender MH. Allergic Conjunctivitis. Immunology and Allergy Clinics of North America. 2008; 8(1): 43-58.

Del Cuvillo A, Sastre J, Montoro J, et al. Allergic Conjunctivitis and H1 Antihistamines. Journal of Investigational Allergology and Clinical Immunology. 2009; 19(1): 11-18.

Amod R. Immunology of Allergic Eye Disease. Current Allergy & Clinical Immunology. 2006; 19: 70-73.4. Bonini S, Sgrulletta R, Coassin M, and Bonini S. Allergic Conjunctivitis: Update on Its Pathophysiology and Perspectives for Future Treatment. In: Pawankar R (Ed). Allergy Frontiers: Clinical Manifestations. Rome: Springer; 2009; p. 25-48.

Kumar V, Abbas A, and Fausto N. Diseases of Immunity. In: Kumar V (Ed). Pathologic Basis of Veterinary Disease 7th edition. Philadelphia: Elsevier Saunders; 2005; p. 194-208.

Mahran M, Hagag M, and Shouman A. Involvement of Interleukin-16 (IL-16) in Allergic Conjunctivitis. Australian Journal of Basic and Applied Sciences. 2009; 3(4): 3266-3272.

Nomura K and Takamura E. Tear IgE Concentrations in Allergic Conjunctivitis. Eye. 1998; 12(2): 296-298.8. Pokharel S, Hah DN, Joshi SN, and Choudhary M. Tearfilm Immunoglobulin E (IgE) Level in Vernal Keratoconjunctivitis by ELIS. Kathmandu University Medical Journal. 2009; 7(26): 104-108.

Moloney G and McCluskey PJ. Classifying and Managing Allergic Conjunctivitis. MedicineToday. 2007; 8(11): 16-21.

Manzouri B, Flynn T, and Ono SJ. Allergic Eye Disease: Pathophysiology, Clinical Manifestation and Treatment. In: Reinhard T (Ed). Cornea and External Eye Disease. Heidelberg: Springer; 2006; p. 209-222

Irfani I. Perbandingan Efektivitas Tetes Mata Natrium Kromoglikat 4% dengan Kalium Pemirolast 0,1% pada Pengobatan Konjungtivitis Vernalis. Majalah Kedokteran Bandung. 2008; 40(4): 187-192.

David G and Shulman MD. Two Mast Cell Stabilizers, Pemirolast Potassium 0,1% and Nedocromil Sodium 2%, in the Treatment of Seasonal Allergic Conjunctivitis: A Comparative Study. Advances in Therapy. 2003; 20(1): 31-40.

Inada N, Soji J, Kato H, Kiely S, Mulyanto, and Sawa M. Clinical Evaluation of Total IgE in Tears of Patients with Allergic Conjunctivitis Disease Using a Novel Application of the Immunochromatography Method. Allergology International. 2009; 58(4): 585-589.

Mediaty A and Neuber K. Total and Specific Serum Ige Decreases with Age in Patients with Allergic Rhinitis, Asthma and Insect Allergy but Not in Patients with Atopic Dermatitis. Immunity and Ageing. 2005; 2(9): 1-6.

Anupama N, Sharma MV, Nagaraja HS, and Bhat MR. The Serum Immunoglobulin E Level Reflects the Severity of Bronchial Asthma. Thai Journal of Physiological Sciences. 2006; 18(3): 35-40.

Kemp SF. Cromolyn and Nedocromil: Nonsteroidal Anti-Inflammatory Therapy for Asthma and Other Allergic Diseases. In: Lieberman P (Ed). Allergic Disease, Diagnosis and Treatment 3rd edition. New York: Humana Press; 2007; p. 367-377.

Gous P, and Ropo A. A Comparative Trial of the Safety and Efficacy of 0.1 Percent Pemirolast Potassium Ophthalmic Solution Dosed Twice or Four Times a Day in Patients with Seasonal Allergic Conjunctivitis. Journal of Ocular Pharmacology and Therapeutics. 2004; 20(2): 139-150.

Downloads

Published

2013-03-04

Issue

Vol. 27 No. 2 (2012)

Section

Research Article

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).